Galena Biopharma, DRL in strategic partnership for NeuVax

US-based Galena Biopharma and Dr. Reddy's Laboratories Ltd have announced a strategic development and commercialisation partnership for former's NeuVax (nelipepimut-S) in India.

NeuVax is a peptide-based vaccine aimed at preventing or delaying the recurrence of breast cancer in cancer survivors who achieve remission after standard of care treatment.

According to a press release issued by Galena, the US drug-maker will licence commercial rights to Dr. Reddy's for NeuVax in breast and gastric cancers and the Indian drug maker will lead the development of NeuVax in gastric cancer, significantly expanding the potential addressable patient population.

Dr. Reddy's Chairman & CEO G V Prasad said the partnership accelerates the company's strong commitment to innovation and efforts to bring newer options for cancer patients.

"We are delighted with our partnership with Galena Biopharma and we believe NeuVax can be a good potential treatment option to prevent the recurrence of breast and gastric cancer," Prasad said.

Galena Biopharm President & CEO Mark J Ahn said the partnership with Dr. Reddy's is consistent with their strategy to expand the clinical utility of NeuVax in unmet medical needs while simultaneously increasing the commercial footprint of this innovative cancer immunotherapy.

"Dr. Reddy's is a leading pharmaceutical company in India with significant commercialisation and development expertise. The gastric cancer trial will add a significant indication to our pipeline for NeuVax, while doubling our potential patient population if approved," Ahn said.

Galena said it will receive development and sales milestones, as well as double-digit royalties on net sales.

According to reports, breast cancer is the most common diagnosed malignancy in women worldwide (22 per cent) and in India (18.5 per cent) it ranks second to cervical cancer.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • 49 per cent FDI in defence should pave the way for modernisation

    There is one industrial sector in India that has been kept out of the purview of the normal cycle of investment and production — defence.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Tushar Gandhi

Welfare must be humanitarian not political

We are a very political people. We politicise and corrupt ...

Purnendu Ghosh

How to distinguish a need from a want?

The day when the annual budget is announced is one ...

Shona Adhikari

Decades apart, yet a common ground in fine art

Today’s column is about two artists born many decades apart, ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture